Back to top
more

AbbVie (ABBV)

(Real Time Quote from BATS)

$202.94 USD

202.94
679,575

+1.26 (0.63%)

Updated Nov 6, 2024 10:16 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (59 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

AbbVie (ABBV) Rinvoq Gets FDA Nod for Active Psoriatic Arthritis

by Zacks Equity Research

The FDA approves AbbVie's (ABBV) Rinvoq for the treatment of adults with active psoriatic arthritis. This is the second FDA-approved indication for the drug.

Lilly (LLY) Phase III Study in Ulcerative Colitis Meets Goal

by Zacks Equity Research

Eli Lilly's (LLY) mirikizumab meets primary and key secondary endpoints in a phase III maintenance study in ulcerative colitis.

Pfizer (PFE) COVID Pill Maintains Strong Efficacy, Stock Up

by Zacks Equity Research

Pfizer's (PFE) COVID-19 pill maintains a substantial reduction in hospitalizations and deaths observed during interim analysis last month in the final analysis of the study data.

SpringWorks (SWTX) & AbbVie Unite for Multiple Myeloma Drug

by Zacks Equity Research

SpringWorks Therapeutics (SWTX) collaborates with AbbVie (ABBV) to evaluate the combination of nirogacestat with AbbVie's ABBV-383 for relapsed or refractory multiple myeloma.

Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

by Zacks Equity Research

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

Kinjel Shah headshot

Pharma Stock Roundup: PFE Booster Works on Omicron, AZN COVID Cocktail Gets FDA Nod

by Kinjel Shah

Pfizer (PFE) and BioNTech's COVID-19 booster shot proves effective against the Omicron variant. FDA grants EUA to AstraZeneca's (AZN) cocktail antibody for pre-exposure prophylaxis (prevention) of COVID-19.

AbbVie (ABBV) Gains As Market Dips: What You Should Know

by Zacks Equity Research

AbbVie (ABBV) closed the most recent trading day at $124.15, moving +1.87% from the previous trading session.

AbbVie's (ABBV) Rinvoq Meets Goals in Crohn's Disease Study

by Zacks Equity Research

AbbVie's (ABBV) Rinvoq achieves primary and key secondary endpoints in the first phase III induction study in patients with Crohn's Disease.

Biohaven (BHVN) Intranasal Migraine Therapy Meets Goal in Study

by Zacks Equity Research

Biohaven's (BHVN) pivotal study evaluating intranasal zavegepant for the acute treatment of migraine in adults meets co-primary endpoints. An NDA for zavegepant is expected to be filed in first-quarter 2022.

AbbVie (ABBV) Adds FDA-Issued New Warnings to Rinvoq's Label

by Zacks Equity Research

AbbVie (ABBV) adds a heart-risk warning on the label of JAK inhibitor medicine, Rinvoq.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Panel Vote for MRK COVID Pill, JNJ Omicron Jab Plan

by Kinjel Shah

FDA panel votes for Merck's (MRK) COVID-19 antiviral pill. AbbVie (ABBV) seeks approval for Skyrizi for Crohn's disease in Europe

Mark Vickery headshot

Top Analyst Reports for Tesla, Meta Platforms & Abbott Laboratories

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Meta Platforms, Inc. (FB), and Abbott Laboratories (ABT).

AbbVie (ABBV) Files for Skyrizi to Treat Crohn's Disease in EU

by Zacks Equity Research

AbbVie (ABBV) submits a regulatory application in the European Union, seeking approval for risankizumab (Skyrizi) for the treatment of Crohn's disease.

Bristol Myers' (BMY) Plaque Psoriasis Drug Filings Get Through

by Zacks Equity Research

Bristol Myers' (BMY) applications seeking approval for deucravacitinib are accepted by the regulatory bodies of both the United States and the European Union.

REGENXBIO (RGNX) DMD Gene Therapy Gets Orphan Drug Status

by Zacks Equity Research

REGENXBIO (RGNX) is developing a gene therapy candidate, RGX-202, for treating DMD, which is currently in the pre-clinical stage. An IND application is expected by the end of 2021.

Pfizer (PFE) Inks $5.3B COVID Pill Supply Deal With U.S.

by Zacks Equity Research

The U.S. government is set to purchase 10 million treatment courses of Pfizer's (PFE) oral pill for COVID-19, Paxlovid, if approved or authorized.

AbbVie's (ABBV) Skyrizi Gets Nod for Psoriatic Arthritis in EU

by Zacks Equity Research

AbbVie (ABBV) secures approval in the EU for Skyrizi to treat adult patients with active psoriatic arthritis.

Kinjel Shah headshot

Pharma Stock Roundup: JNJ to Spin Off Consumer Unit, PFE Eyes EUA for COVID Pill

by Kinjel Shah

J&J (JNJ) decides to split into two companies. Pfizer (PFE) seeks nod for emergency use of COVID antiviral pill. Glaxo's (GSK) and AbbVie's (ABBV) drugs get approvals in new indications.

Biohaven (BHVN) Misses on Q3 Earnings, Inks $1.24B Pfizer Deal

by Zacks Equity Research

Biohaven's (BHVN) sole approved drug, Nurtec ODT, for treating migraine, continues to demonstrate strong demand in the United States. The company signs an agreement with Pfizer, granting the latter ex-U.S. marketing rights to Nurtec ODT.

Editas (EDIT) Q3 Earnings Beat Estimates, Revenues Fall Y/Y

by Zacks Equity Research

Editas (EDIT) reports narrower-than-expected loss in the third quarter of 2021 while its revenues marginally beat estimates. Focus remains on the development of lead candidate, EDIT-101.

Reata (RETA) Stock Up Following Q3 Earnings & Sales Beat

by Zacks Equity Research

Reata (RETA) beats estimates for earnings and sales. An advisory committee meeting is scheduled on Dec 8 to discuss bardoxolone NDA.

The Zacks Analyst Blog Highlights: Tesla, Comcast, AbbVie, Boeing, China Petroleum & Chemical and Advanced Micro Devices

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Tesla, Comcast, AbbVie, Boeing, China Petroleum & Chemical and Advanced Micro Devices

Sheraz Mian headshot

Top Analyst Reports for Tesla, Comcast & AbbVie

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Comcast (CMCSA), and AbbVie Inc. (ABBV).

Ironwood (IRWD) Q3 Earnings Top, Sales Hurt by Lower Price

by Zacks Equity Research

Ironwood (IRWD) witnesses flat year-over-year sales as growth in demand for Linzess gets partially offset by lower net price of the drug. The company maintains revenue guidance. Stock down.

Editas (EDIT) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Editas' (EDIT) third-quarter earnings call, investor focus will likely be on the company's progress with the development of its lead pipeline candidate, EDIT-101.